Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Replidyne has initiated phase I clinical testing of its topical anti-infective drug candidate REP8839, being developed for treatment of skin and wound infections and the prevention of S. aureus infections including MRSA.
Subscribe to our email newsletter
REP8839 is being developed in combination with mupirocin, a widely used topical antibiotic.
The study will examine various concentrations of REP8839 alone and in combination with mupirocin versus a placebo control in a total of 110 healthy adults. The clinical endpoint is an evaluation of the irritancy of repeat applications of REP8839 alone and a REP8839/mupirocin combination to intact and abraded skin with daily dosing duration of 2, 14 and 21 days.
“We believe that REP8839 has the potential to be a significant addition to the treatment options for S. aureus infections, including those caused by MRSA,” said Kenneth Collins, president and CEO.
This study is the initial phase I clinical trial for REP8839. It is anticipated that up to three phase I clinical trials focused on treating skin and wound infections will be conducted for REP8839 in combination with mupirocin.